News
PRPH
6.26
-0.48%
-0.03
Weekly Report: what happened at PRPH last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at PRPH last week (0311-0315)?
Weekly Report · 03/18 09:51
PRPH Stock Earnings: ProPhase Labs Misses EPS, Misses Revenue for Q4 2023
ProPhase Labs reported earnings per share of -51 cents. The company reported revenue of $4.35 million. This was 59.30% below the analyst estimate for the company to report revenue of  $10.69 million. The company also reported lower than expected earnings.
Investorplace · 03/15 16:53
ProPhase Labs Q4 EPS $(0.51) Misses $(0.26) Estimate, Sales $4.35M Miss $10.69M Estimate
ProPhase Labs reports quarterly losses of $0.51 per share. The company reported quarterly sales of $4.35 million. ProPhase Labs missed the analyst consensus estimate of $10.69 million by 59.30%. The company also missed the quarterly sales estimate by 80.06%.
Benzinga · 03/15 12:10
*ProPhase Labs 2023 Loss/Shr $0.98 >PRPH
Dow Jones · 03/15 12:02
ProPhase Labs GAAP EPS of -$0.98 misses by $0.24, revenue of $45.2M misses by $6.38M
Seeking Alpha · 03/15 12:01
*ProPhase Labs 2023 Rev $45.2M >PRPH
Dow Jones · 03/15 12:01
BRIEF-ProPhase Labs FY Adjusted EBITDA USD -10.558 Million
Reuters · 03/15 12:00
Earnings Scheduled For March 15, 2024
NeoGenomics is expected to report quarterly earnings at $0.17 per share on revenue of $182.13 million. EHang Holdings is also projected to report earnings for its fourth quarter. Other companies reporting before the bell and after the bell include Prestige Consumer and Buckle.
Benzinga · 03/15 09:15
ProPhase Labs FY 2023 Earnings Preview
Seeking Alpha · 03/14 17:11
ProPhase Labs's Earnings: A Preview
ProPhase Labs is set to give its latest quarterly earnings report on Friday, 2024-03-15. Analysts estimate the company will report an earnings per share of $-0.26. Last quarter the company missed EPS by $0.11. Shares of ProPhase Labs were trading at $5.05 as of March 13.
Benzinga · 03/14 15:00
Notable earnings before Friday's open
Major earnings expected before the bell on Friday include: The Buckle, Groupon and Jabil. Other major earnings slated for release before Friday's open include: EHang Holdings, Jabil and SMLP. Notable earnings before the open include JBL, EH, ZDGE and Groupon. For the earnings season calendar, click here.
Seeking Alpha · 03/14 14:09
Prophase Labs Inc <PRPH.OQ> expected to post a loss of 26 cents a share - Earnings Preview
Prophase Labs Inc expected to report a 51.0% fall in quarterly revenue to $10.688 million. The company is expected to post a loss of 26 cents a share. The one available analyst rating on the shares is 'buy' for the New York-based company.
Reuters · 03/13 12:39
Weekly Report: what happened at PRPH last week (0304-0308)?
Weekly Report · 03/11 09:50
Weekly Report: what happened at PRPH last week (0226-0301)?
Weekly Report · 03/04 09:51
Weekly Report: what happened at PRPH last week (0219-0223)?
Weekly Report · 02/26 09:56
ProPhase Labs Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
Dow Jones · 02/21 18:30
HC Wainwright & Co. Reiterates Buy on ProPhase Labs, Maintains $11 Price Target
Benzinga · 02/21 18:20
Analysts Offer Insights on Healthcare Companies: Prophase Labs (PRPH) and Crispr Therapeutics AG (CRSP)
TipRanks · 02/21 17:00
Weekly Report: what happened at PRPH last week (0212-0216)?
Weekly Report · 02/19 09:57
More
Webull provides a variety of real-time PRPH stock news. You can receive the latest news about Prophase Labs Inc through multiple platforms. This information may help you make smarter investment decisions.
About PRPH
ProPhase Labs, Inc. is a diagnostics, genomics and biotech company. The Company leverages its Clinical Laboratory Improvement Amendments (CLIA) lab services to provide whole genome sequencing and research direct to consumers and build a genomics database to be used for further research. It provides traditional CLIA molecular laboratory services, including coronavirus disease (COVID-19) testing. It also operates Pharmaloz, a contract manufacturing subsidiary, which offers the TK Supplements line of dietary supplements, which are distributed in food, drug, and mass stores. The Company's wholly owned subsidiary ProPhase Diagnostics, Inc, offers a broad array of clinical diagnostic and testing services at its CLIA-certified laboratories including polymerase chain reaction (PCR) testing for SARS-CoV-2 (COVID-19) and Influenza A and Influenza B. It also owns the exclusive rights to the BE-Smart Esophageal Pre-Cancer Diagnostic Screening test.